Benefits with modeling circulating tumor cell counts as a predictor of overall survival

We would like to bring everyone’s attention to a recent publication highlighting the benefits of an innovative quantitative modeling framework. The framework uses circulating tumor cell counts as a predictor of overall survival in metastatic colorectal cancer. Dr. Ida Neldemo (previously Netterberg), main author of the publication, conducted this work before joining Pharmetheus, during her PhD under the supervision of Pharmetheus’ advisors Prof. Mats Karlsson and Prof. Lena Friberg. Find the article here.

Pharmetheus stands ready to apply the principles of this publication to our client’s drug development program.